INTRODUCTION
Despite treatment advances, 1 the United States HIV epidemic remains a serious public health dilemma. 2, 3 The Centers for Disease Control and Prevention (CDC) estimates that as of 2006, 1.1 million adults and adolescents were living with HIV, 232,700 (21.0%) of them undiagnosed. 4 Furthermore, the CDC projects that 56,300 persons became newly infected with HIV during 2006, 5 many of whom may not seek testing until latestage infection. 6 Conventional HIV screening policies have required patients to opt in to testing via stringent written consent procedures exceeding those historically required to screen for other communicable diseases. 7 Proposals to detect and treat more HIV-infected persons earlier in the course of infection have included streamlining the opt-in consent process by simplifying written consent forms 8 and accepting verbal consent in lieu of signed forms. 9, 10 In 2006 the CDC recommended an opt-out approach whereby patients in all healthcare settings are tested unless they explicitly decline. 11 Observational studies report that each of these streamlined consent strategies yields statistically significant increases in HIV diagnosis rates compared to conventional written opt-in testing. [8] [9] [10] 12 Some states have already changed their HIV testing consent laws in response to the CDC recommendations; however, laws in many states still require conventional opt-in consent. 13, 14 One potential consequence of these written opt-in consent laws is less frequent testing resulting in delays in diagnosis until more advanced immunosuppression. Such delays may be associated with decreased survival for HIV-infected persons due to later initiation of antiretroviral treatment (ART). 15 Our objective was to project the survival gain of revising these state laws, given alternative assumptions regarding the impact of consent laws on rates of HIV diagnosis and linkage to care.
METHODS

Analytic Overview
As The monthly risk of non-AIDS-related death for all individuals is age-specific and sex-specific. 23 The model simulates millions of patients' lifetimes to achieve statistical convergence. Monthly probabilities of transition between health states are affected by treatment. Opportunistic infection prophylaxis reduces the CD4-dependent risk of acute disease. ART reduces HIV RNA with a concomitant increase in CD4 count, and a resultant decrease in the probabilities of HIV-related death and opportunistic infection. Patients experiencing ART failure (two successive HIV RNA levels indicative of virological rebound) transition to successive lines of treatment (up to 6). 1 
Screening Model Overview
Whereas the Disease Model simulates disease progression in HIV-infected persons only, the Screening Model simulates HIV infection and case detection in populations including infected and uninfected individuals. 18 The Screening Model regulates entry into the Disease Model, defining population epidemic characteristics which determine whether and when population members become infected with HIV (undiagnosed prevalence, incidence). In conjunction with the Disease Model, the Screening Model also determines whether and when HIV-infected patients are identified and linked to care, both prerequisites for treatment; HIV diagnosis and linkage to care may occur via either a screening program or presentation with opportunistic infection (diagnostic testing).
Input Data (Table 1) In addition to baseline diagnosis rates, other Screening Model inputs included 0.101% undiagnosed HIV prevalence in written opt-in states, as determined using the estimates of numbers of unidentified HIV-infected persons derived from CDC data. 2, 4 We assumed 0.023% annual incidence based on CDC calculations. 5 Published data provided estimates of HIV test sensitivity (99.6%) and specificity (97.5%) and the linkage-to-care probability for newly-diagnosed HIV-infected persons (75.0%). 18 The monthly probabilities of transition between health states in the Disease Model reflect data from cohort studies and randomized clinical trials. Data describing the natural history of untreated HIV (CD4 count decline, incidence of opportunistic infection, and HIV-related mortality) and distributions of CD4 counts and HIV RNA in the HIV-infected population are derived from the Multicenter AIDS Cohort Study 22 and the literature. 24 Patient care is assumed to conform to national guidelines: quarterly CD4 and HIV RNA measurements 25 to dictate initiation, termination, or switching of opportunistic infection prophylaxis 26 and ART regimens. 25 The effects of these treatments on patients' monthly transition probabilities reflect data on the efficacy (Table 1) of ART [27] [28] [29] [30] [31] [32] [33] and OI prophylaxes.
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Additional Sensitivity Analyses
First, to evaluate concerns that a switch to opt-out testing might discourage people from accessing healthcare, we examined the survival effects of scenarios in which the diagnosis rate among HIV-infected persons in written opt-in states decreased by 25%, 50%, 75%, and 100% in response to a transition to verbal consent. Second, we varied the baseline diagnosis rate estimate for written opt-in states from half (9.6%) to double (38.5%) the 19.3% base-case value. Third, we considered scenarios of high and low combined undiagnosed prevalence and incidence with input ranges based on the confidence intervals of CDC estimates of national prevalence (±4.5% of baseline undiagnosed prevalence) 4 and incidence (±14.5% of baseline incidence). 5 Additional sensitivity analyses examined the impact of varying other major Disease and Screening Model parameter inputs from 50-200% of base-case values, including ART efficacy, opportunistic infection incidence rates, and cohort viral load distribution.
RESULTS
Survival Gains Associated with Consent Law
In the base-case scenario, a 48.5% diagnosis rate increase in written opt-in states from 19.3% to 28.7% results in improved patient outcomes ( Abbreviations: ATV/r-atazanavir sulfate with ritonavir; AZT-zidovudine; EFV-efavirenz; FTC-emtricitabine; LPV/r-lopinavir with ritonavir; OBRoptimized background regimen as chosen with the aid of genotypic and phenotypic HIV resistance testing; RAL-raltegravir; SD-standard deviation; ENF-enfuvirtide; TDF-tenofovir disoproxil fumarate * Estimates derived from national data sources; prevalence values were validated using the opt-in state prevalence estimates calculated in Table 2 † Value is for patient post-seroconversion; pre-seroconversion sensitivity parameter set to 2.5%
18 ‡ Pre-and post-seroconversion specificities assumed to be equivalent 18 
Potential Impact of Healthcare Avoidance
Regarding scenarios in which HIV-infected persons living in written opt-in states avoid HIV testing in response to laws relaxing consent requirements, 18.2% of HIV-infected persons must cease all testing to offset survival gains (solid arrow, Fig. 1) . Alternatively, 37.3% of the HIV-infected population must receive testing half as often as they do with written opt-in consent to negate survival gains (hollow arrow, Fig. 1 ).
Variations in Baseline Diagnosis Rate
The estimated baseline diagnosis rate in written opt-in states also affects survival gain projections (Fig. 2a) . Survival gains are stable when the current diagnosis rate is reduced by half from 19.3% to 9.6% (triangles, Fig. 2a ): a 48.5% diagnosis rate increase with the low baseline diagnosis rate results in a total survival gain of 491,503 LYG (solid arrow, Fig. 2a ). However, a 48.5% diagnosis rate increase when the current diagnosis rate is doubled from 19.3% to 38.5% results in a total survival gain of 377,568 LYG (hollow arrow, Fig. 2a ).
Variations in Baseline HIV Incidence/Prevalence
Projected survival gains also rely upon the undiagnosed HIV prevalence and incidence of the population living in written opt-in states (Fig. 2b) . In a scenario of high undiagnosed prevalence (0.106%) and incidence (0.026%), a 48.5% diagnosis rate increase yields 612,213 LYG (solid arrow, Fig. 2b) . In a scenario of low undiagnosed prevalence (0.096%) and incidence (0.020%), the same diagnosis rate increase yields 454,187 LYG (hollow arrow, Fig. 2b ).
Other Sensitivity Analyses
Plausible variation in other major Disease and Screening Model input parameters generally did not result in material or informative changes in outcomes. Study results remained largely unchanged although to the extent that simulated care was less effective (e.g., poor ART efficacy or availability), survival gains decreased.
DISCUSSION
This analysis projects a survival gain exceeding half a million LYG associated with a 48.5% increase in HIV diagnosis rate which may be achieved by revising consent laws in nine states requiring written opt-in consent. Based on this same diagnosis rate increase, we further estimate a survival gain of 789,565 LYG achieved by the 12 states which have already removed the requirement for written opt-in consent since release of the CDC recommendations for opt-out HIV testing. These survival gains are sensitive to the diagnosis rate increase associated with revised laws. Varying this parameter according to the confidence interval reported by Zetola et al. (24.8-72 .3%) 10 results in survival gains ranging from 304,765 to 724,195 LYG Figure 1 . Impact of nonparticipation on survival gains. Nonparticipation is quantified by the percent decrease in diagnosis rates compared to current (written opt-in) testing practice (horizontal axis) and the proportion of the HIV-infected population exhibiting that decrease (vertical axis). The solid line represents the frontier along which expanded screening yields exactly zero survival gains. The space above and to the right of the frontier represents scenarios in which nonparticipation offsets and reverses the basecase scenario survival gains attributable to revised consent laws, leading to a net survival loss. In contrast, the space below and to the left of the frontier represents scenarios in which nonparticipation is insufficient to offset all survival gains due to expanded screening. To offset survival gains, 18.2% would need to cease all testing (solid arrow) or 37.3% of the HIV-infected population would need to decrease their testing rates half (hollow arrow) in response to revised consent laws. in states still requiring written opt-in consent and from 447,772 to 1,064,012 LYG in states which have already removed this requirement. These survival gains compare favorably with those of other accepted health policy initiatives. The survival gain of 0.12 months per member of the general population exceeds that for vaccinating infants against measles, mumps, rubella, or pertussis; vaccinating adults against hepatitis B; or biennial mammography for women >50 years of age. 41 Furthermore,
there is an extensive literature suggesting that expansion of HIV testing as simulated by this study would be cost-effective. [18] [19] [20] Our finding that new consent laws might yield substantial survival gains is robust to broad sensitivity analyses. Notably, nearly one-fifth of HIV-infected persons would need to suspend all contact with the healthcare system in response to new laws to yield a net survival loss. This result speaks to concerns voiced since the early days of the HIV epidemic regarding measures to streamline the testing consent process. Specifically, some have noted that if streamlined consent laws were misinterpreted as an endorsement of involuntary testing, it is possible that diagnosis rates would decrease as infected persons refuse to present to healthcare facilities. 42 To our Figure 2 . a. Impact of baseline diagnosis rate on survival gains. Base-case survival gains are similar in scenarios of base-case (diamonds) and half of base-case (triangles) baseline diagnosis rates. Assuming a 48.5% diagnosis rate increase given the low baseline diagnosis rate resulted in a total survival gain of 491,503 LYG (solid arrow); the slightly lower value when compared to the base-case is likely attributable to the smaller magnitude of diagnosis rate increase. Scenarios with the baseline diagnosis rate set to double the base-case value (squares) resulted in survival gains significantly lower than those for base-case scenarios, reflecting a leveling off of survival gains as diagnosis rates rise. Assuming a 48.5% diagnosis rate increase given the high baseline diagnosis rate resulted in a total survival gain of 377,568 LYG (hollow arrow). b Impact of undiagnosed prevalence and incidence on survival gains. Base-case survival gains assume 0.101% undiagnosed prevalence and 0.023% incidence (diamonds). In scenarios of high undiagnosed prevalence (0.106%) and incidence (0.026%) survival gains are higher (squares), reaching 612,213 LYG assuming a 48.5% diagnosis rate increase (solid arrow). Conversely, in scenarios of low undiagnosed prevalence (0.096%) and incidence (0.020%) survival gains are lower (triangles), reaching 454,187 LYG assuming a 48.5% diagnosis rate increase (hollow arrow).
knowledge, there are no data to suggest that any such avoidance would result from streamlining the consent process. The survival gains projected by our analysis are based on a diagnosis rate increase estimate extrapolated from a San Francisco-based study examining changes in rates of positive HIV test results associated with the transition from written to verbal opt-in HIV testing. 10 While positive test rates are not necessarily equivalent to diagnosis rates, they are likely to be a much closer approximation than are the testing rates otherwise reported in the literature. 8, 12 Nevertheless, there is a paucity of literature informing the effect of consent law on diagnosis rates and the generalizability of the San Francisco results is uncertain. Moreover, a recent study found that New York state increased HIV testing rates by 31.4% by merely simplifying its consent form. 8 This finding suggests the diagnosis rate change following removal of written opt-in consent will be unique in each state, depending on the extent to which each jurisdiction's consent form poses a testing barrier, yet our study assumes a uniform effect in all states. While further research might consider the heterogeneity in written opt-in states' consent forms, the absence of such sitespecific data now makes it difficult to interpret the implications of the uniform effect assumption for our results. Regardless, our study likely understates the possible survival benefits of consent law revision as the 48.5% base-case diagnosis rate increase value used is that reported for the transition from written opt-in to verbal opt-in consent rather than the more ambitious transition recommended by the CDC 11 to opt-out consent. Indeed, data from England indicate that the transition from written opt-in to opt-out consent as recommended by the CDC could yield a testing rate increase of 85.7%. 12 Furthermore, the base-case applies a 48.5% diagnosis rate increase only to states requiring written opt-in consent, ignoring potential survival gains that may be attributed to transitioning to opt-out consent in verbal opt-in states. This study has several additional limitations. First, the model is not dynamic; consequently, the simulations assumed a constant incidence rate, likely a reasonable assumption over at least the next ten years. Second, the model does not simulate survival gains from preventing secondary transmission due to HIV-infected persons' earlier knowledge of their serostatus, an omission likely to underestimate the survival benefits of revised consent laws. Third, the model does not simulate members of future generations whom may become infected with HIV and so would eventually benefit from law changes facilitating more frequent testing now, another limitation likely to bias our results against revised laws. Finally, the assumption that all monitoring and treatment of HIVinfected persons conforms to national guidelines portrays screening favorably. Our sensitivity analyses confirm that the survival gains of expanded screening depend upon treatment access and efficacy. Expanded screening becomes less attractive to the extent that certain populations receive substandard care. 43 Opt-in state HIV testing consent laws exemplify "HIV exceptionalism," a legacy of the early HIV epidemic during which the disease was poorly understood, untreatable, and primarily confined to well-defined risk groups already stigmatized by society. 42 In that context opt-in testing protected HIVinfected persons from a diagnosis associated with discrimination and little medical benefit. Patient protection and consent remain important today, but now must be balanced against the dramatic health benefits made possible by ART. 1 The CDC's recommendations offer a pragmatic approach to achieving this balance, aligning the HIV testing process with that used when screening for other treatable communicable diseases. While many states have adjusted their laws accordingly, numerous states still require opt-in consent.
14 For those states whose laws continue to require written optin testing, this study highlights the potential value of urgent legislation to remove any requirement for written opt-in consent. Failure to revise these obsolete laws is to risk an opportunity cost which in aggregate may exceed half a million years of human life.
